{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:29:39Z","timestamp":1793431779967,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100023993","name":"North Carolina Collaboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.japh.2026.103472","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:00:43Z","timestamp":1781798443000},"page":"103472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Barriers and facilitators to pharmacy-based methadone dosing and dispensing: Semi-structured interviews with pharmacists"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-0631","authenticated-orcid":false,"given":"Grace T.","family":"Marley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ava","family":"Nunnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8044-9838","authenticated-orcid":false,"given":"Caroline","family":"Shubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-8140","authenticated-orcid":false,"given":"Delesha","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-3747","authenticated-orcid":false,"given":"Bayla","family":"Ostrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.japh.2026.103472_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.japh.2026.103472_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00952990.2019.1620261","article-title":"Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment","volume":"46","author":"Amiri","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.japh.2026.103472_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108727","article-title":"Access to medication-assisted treatment in the United States: comparison of travel time to opioid treatment programs and office-based buprenorphine treatment","volume":"224","author":"Amiri","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt's like 'liquid handcuffs\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.japh.2026.103472_bib6","article-title":"Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone","volume":"6","author":"Carl","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"issue":"S2","key":"10.1016\/j.japh.2026.103472_bib7","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","article-title":"The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists","volume":"112","author":"Simon","year":"2022","journal-title":"Am J Public Health"},{"key":"10.1016\/j.japh.2026.103472_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2025.104805","article-title":"Barriers to accessing medications for opioid use disorder among rural individuals","volume":"140","author":"Morenz","year":"2025","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.japh.2026.103472_bib9","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2026.103472_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/SAR.S351096","article-title":"The role of the pharmacist in combating the opioid crisis: an update","volume":"13","author":"Kosobuski","year":"2022","journal-title":"Subst Abuse Rehabil"},{"key":"10.1016\/j.japh.2026.103472_bib12","author":"Sen. Markey"},{"key":"10.1016\/j.japh.2026.103472_bib15","article-title":"Barriers and facilitators to methadone dispensing for opioid use disorder in community pharmacies: a scoping review","volume":"18","author":"Shubel","year":"2026","journal-title":"Drug Alcohol Depend Rep"},{"issue":"2","key":"10.1016\/j.japh.2026.103472_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2024.102319","article-title":"Community pharmacy-based buprenorphine programs and pharmacists' roles, knowledge, attitudes, and barriers to providing buprenorphine-related services: a systematic review","volume":"65","author":"Rawal","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2026.103472_bib18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/add.15641","article-title":"Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial","volume":"117","author":"Wu","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2026.103472_bib19","article-title":"Opioid treatment program prescribing of methadone with community pharmacy dispensing: pilot study of feasibility and acceptability","volume":"3","author":"Brooner","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.japh.2026.103472_bib20","author":"Woodruff"},{"issue":"4","key":"10.1016\/j.japh.2026.103472_bib22","article-title":"Actions of the 2024 American Pharmacists Association House of Delegates, Orlando, FL, March 22 \u2013 25, 2024","volume":"64","year":"2024","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.japh.2026.103472_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109495","article-title":"County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019","volume":"236","author":"Corry","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2026.103472_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.japh.2026.103472_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001742","article-title":"Community pharmacist perspectives on observing and dispensing methadone for opioid use disorder: cross-sectional survey study","author":"Carpenter","year":"2026","journal-title":"J Addict Med"},{"key":"10.1016\/j.japh.2026.103472_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/29767342261449037","article-title":"Expanding methadone access through community pharmacies: a qualitative study exploring opioid treatment program staff perceptions of pharmacy-based medication units","author":"Shubel","year":"2026","journal-title":"Subst Use Addctn J"},{"key":"10.1016\/j.japh.2026.103472_bib28","article-title":"Perspectives from opioid treatment program staff on community pharmacy-based methadone dispensing in North Carolina","volume":"186","author":"Shubel","year":"2026","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.japh.2026.103472_bib29","article-title":"Methadone in community pharmacies: a mixed methods evaluation of board-certified addiction medicine physicians and addiction psychiatrists perspectives","volume":"190","author":"Marley","year":"2026","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.japh.2026.103472_bib30","article-title":"Methadone at the pharmacy like Suboxone\u00ae?\u2026 It would untangle a lot of tangles.\u201d \u2013 perspectives of North Carolinians with lived experience of opioid use on potential benefits of methadone dispensing at community pharmacies","volume":"1","author":"Ostrach","year":"2026","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.japh.2026.103472_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.japh.2026.103472_bib33","series-title":"MAXQDA 24 [Computer Software]","year":"2026"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"issue":"3","key":"10.1016\/j.japh.2026.103472_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.102348","article-title":"Pharmacy harm reduction practices to help reduce opioid overdoses, Arizona 2023","volume":"65","author":"Meyerson","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"9","key":"10.1016\/j.japh.2026.103472_bib36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1377\/hlthaff.2025.00344","article-title":"Key-informant perspectives on pharmacy-based methadone treatment for opioid use disorder in the US","volume":"44","author":"Stewart","year":"2025","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"10.1016\/j.japh.2026.103472_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.0703","article-title":"Treating opioid use disorder with methadone in pharmacies","volume":"9","author":"Tschampl","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.japh.2026.103472_bib38","article-title":"US payment policy for medications to treat opioid use disorder: landscape and opportunities","volume":"2","author":"McGinty","year":"2024","journal-title":"Health Aff Sch"},{"issue":"9","key":"10.1016\/j.japh.2026.103472_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.3239","article-title":"Coverage for opioid use disorder medications in Medicaid managed care","volume":"6","author":"Andrews","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.japh.2026.103472_bib41","author":"Team"},{"issue":"4","key":"10.1016\/j.japh.2026.103472_bib42","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/dar.13437","article-title":"Examining the cost and impact of dosing fees among clients in opioid agonist treatment: results from a cross-sectional survey of Australian treatment clients","volume":"41","author":"Zahra","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.japh.2017.10.015","article-title":"Advancing the role of the pharmacy technician: a systematic review","volume":"58","author":"Mattingly","year":"2018","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"10.1016\/j.japh.2026.103472_bib46","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.japh.2021.11.011","article-title":"Pharmacy technician-administered immunizations: a five-year review","volume":"62","author":"Adams","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"10.1016\/j.japh.2026.103472_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2025.102423","article-title":"Evaluation of work activities for pharmacists in community pharmacy settings","volume":"65","author":"Schenkelberg","year":"2025","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2026.103472_bib48","article-title":"Availability of and attitudes towards harm reduction services: a rural pharmacy perspective","volume":"65","author":"Marley","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2026.103472_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211022994","article-title":"U.S. student pharmacist perceptions of the pharmacist's role in methadone for opioid use disorder: a qualitative study","volume":"9","author":"Hohmeier","year":"2021","journal-title":"SAGE Open Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103472_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ADM.0000000000001244","article-title":"A brief online training to address pharmacists' willingness to dispense buprenorphine","volume":"18","author":"Carpenter","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.japh.2026.103472_bib51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00952990.2026.2654473","article-title":"Self-reported differences between liquid and tablet methadone in persons with opioid use disorder","volume":"52","author":"Dunn","year":"2026","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126004577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126004577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:38:01Z","timestamp":1788190681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126004577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1544319126004577"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103472","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators to pharmacy-based methadone dosing and dispensing: Semi-structured interviews with pharmacists","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"103472"}}